Kromek Group PLC Notice of Results (5331A)
23 Gennaio 2024 - 8:00AM
UK Regulatory
TIDMKMK
RNS Number : 5331A
Kromek Group PLC
23 January 2024
23 January 2024
Kromek Group plc
("Kromek" or the "Group")
Notice of Results
Kromek Group plc (AIM: KMK), a leading developer of radiation
and bio-detection technology solutions for the advanced imaging and
CBRN detection segments, gives notice that it will be announcing
its interim results for the six months ended 31 October 2023 on
Tuesday 30 January 2024.
Dr Arnab Basu, Chief Executive Officer, and Paul Farquhar, Chief
Financial Officer, will be hosting a presentation for investors at
6pm GMT on Wednesday 31 January 2024 via webinar. The webinar is
open to all existing and potential shareholders. Interested parties
can register to attend, and submit questions in advance, using the
following link: https://forms.gle/eRXGNiuCnmH3yGov9 . Participants
are requested to submit questions by 12pm on 31 January 2024.
For further information, please contact:
Kromek Group plc
Arnab Basu, CEO
Paul Farquhar, CFO +44 (0)1740 626 060
Cavendish Capital Markets Limited (Nominated
Adviser and Broker)
Geoff Nash/Giles Balleny/Seamus Fricker -
Corporate Finance
Tim Redfern - ECM
Michael Johnson/Tamar Cranford-Smith - Sales +44 (0)20 7220 0500
Gracechurch Group (Financial PR)
Harry Chathli/Claire Norbury/Henry Gamble +44 (0)20 4582 3500
Kromek Group plc
Kromek Group plc is a leading developer of radiation detection
and bio-detection technology solutions for the advanced imaging and
CBRN detection segments. Headquartered in County Durham, UK, Kromek
has manufacturing operations in the UK and US, delivering on the
vision of enhancing the quality of life through innovative
detection technology solutions.
The advanced imaging segment comprises the medical (including CT
and SPECT), security and industrial markets. Kromek provides its
OEM customers with detector components, based on its core cadmium
zinc telluride (CZT) platform, to enable better detection of
diseases such as cancer and Alzheimer's, contamination in
industrial manufacture and explosives in aviation settings.
In CBRN detection, the Group provides nuclear radiation
detection solutions to the global homeland defence and security
market. Kromek's compact, handheld, high-performance radiation
detectors, based on advanced scintillation and solid-state readout
technology, are primarily used to protect critical infrastructure,
events, personnel and urban environments from the threat of 'dirty
bombs'.
The Group is also developing bio-security solutions in the CBRN
detection segment. These consist of fully automated and autonomous
systems to detect a wide range of airborne pathogens.
Kromek is listed on AIM, a market of the London Stock Exchange,
under the trading symbol 'KMK'.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORSEWEEEELSEDF
(END) Dow Jones Newswires
January 23, 2024 02:00 ET (07:00 GMT)
Grafico Azioni Kromek (LSE:KMK)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Kromek (LSE:KMK)
Storico
Da Dic 2023 a Dic 2024
